Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors

NAActive, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

February 22, 2026

Study Completion Date

February 22, 2026

Conditions

Neuroendocrine Tumors

Interventions

DRUG

F18-FDG

Evaluate FDG uptake

Trial Locations (1)

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors

collaborator

Canadian Neuroendocrine Tumour Society (CNETS)

UNKNOWN

lead

University Health Network, Toronto

OTHER